文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

巴雷特食管恶性进展的风险分层:性别、年龄、监测持续时间和年份

Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.

作者信息

Gatenby Piers, Bhattacharjee Santanu, Wall Christine, Caygill Christine, Watson Anthony

机构信息

Piers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.

出版信息

World J Gastroenterol. 2016 Dec 28;22(48):10592-10600. doi: 10.3748/wjg.v22.i48.10592.


DOI:10.3748/wjg.v22.i48.10592
PMID:28082811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5192270/
Abstract

AIM: To clarify risk based upon segment length, diagnostic histological findings, patient age and year of surveillance, duration of surveillance and gender. METHODS: Patients registered with the United Kingdom Barrett's Oesophagus Registry from 9 United Kingdom centers were included. The outcome measures were (1) development of all grades of dysplasia; (2) development of high-grade of dysplasia or adenocarcinoma; and (3) development of adenocarcinoma. Prevalent cases and subjects with < 1 year of follow-up were excluded. The covariates examined were segment length, previous biopsy findings, age at surveillance, duration of surveillance, year of surveillance and gender. RESULTS: One thousand and one hundred thirty six patients were included (total 6474 patient-years). Fifty-four patients developed adenocarcinoma (0.83% per annum), 70 developed high-grade dysplasia/adenocarcinoma (1.1% per annum) and 190 developed any grade of dysplasia (3.5% per annum). High grade dysplasia and adenocarcinoma increased with age and duration of surveillance. The risk of low-grade dysplasia development was not dependent on age at surveillance. Segment length and previous biopsy findings were also significant factors for development of dysplasia and adenocarcinoma. CONCLUSION: The risk of development of low-grade dysplasia is independent of age at surveillance, but high-grade dysplasia and adenocarcinoma were more commonly found at older age. Segment length and previous biopsy findings are also markers of risk. This study did not demonstrate stabilisation of the metaplastic segment with prolonged surveillance.

摘要

目的:根据病变段长度、诊断性组织学结果、患者年龄、监测年份、监测时长及性别来明确风险。 方法:纳入来自英国9个中心在英国巴雷特食管注册处登记的患者。观察指标为:(1)各级发育异常的发生情况;(2)高级别发育异常或腺癌的发生情况;(3)腺癌的发生情况。排除现患病例及随访时间不足1年的受试者。所检查的协变量包括病变段长度、既往活检结果、监测时年龄、监测时长、监测年份及性别。 结果:共纳入1136例患者(总计6474患者年)。54例患者发生腺癌(每年0.83%),70例发生高级别发育异常/腺癌(每年1.1%),190例发生任何级别的发育异常(每年3.5%)。高级别发育异常和腺癌随年龄及监测时长增加。低级别发育异常发生风险不依赖于监测时年龄。病变段长度和既往活检结果也是发育异常和腺癌发生的重要因素。 结论:低级别发育异常发生风险与监测时年龄无关,但高级别发育异常和腺癌在老年患者中更常见。病变段长度和既往活检结果也是风险标志物。本研究未显示延长监测时间后化生段会趋于稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/d6a667b43c33/WJG-22-10592-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/ff1d09fc9fa6/WJG-22-10592-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/cd41cb76493a/WJG-22-10592-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/f38f6a9b6d1c/WJG-22-10592-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/305fff247824/WJG-22-10592-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/5d644ebdad49/WJG-22-10592-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/d6a667b43c33/WJG-22-10592-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/ff1d09fc9fa6/WJG-22-10592-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/cd41cb76493a/WJG-22-10592-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/f38f6a9b6d1c/WJG-22-10592-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/305fff247824/WJG-22-10592-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/5d644ebdad49/WJG-22-10592-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a7a/5192270/d6a667b43c33/WJG-22-10592-g006.jpg

相似文献

[1]
Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.

World J Gastroenterol. 2016-12-28

[2]
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.

Am J Gastroenterol. 2005-4

[3]
Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.

Am J Gastroenterol. 1997-11

[4]
Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.

Dig Dis Sci. 2003-8

[5]
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Am J Gastroenterol. 1999-12

[6]
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.

Dis Esophagus. 2017-3-1

[7]
Chronology of the Barrett's metaplasia-dysplasia-carcinoma sequence.

Dis Esophagus. 2004

[8]
Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.

Am J Gastroenterol. 2012-1-24

[9]
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.

Am J Gastroenterol. 1999-8

[10]
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

J Natl Cancer Inst. 2011-6-16

引用本文的文献

[1]
Navigating Endoscopic Surveillance and Management of Barrett's Esophagus in Elderly Patients: Balancing the Risks and Benefits.

Curr Gastroenterol Rep. 2025-6-9

[2]
Artificial intelligence in endoscopy: Overview, applications, and future directions.

Saudi J Gastroenterol. 2023

[3]
Gastrointestinal Tract Disorders in Older Age.

Can J Gastroenterol Hepatol. 2019-1-17

[4]
Endoscopic therapy for confirmed low-grade dysplasia in Barrett's esophagus.

Transl Gastroenterol Hepatol. 2018-10-29

[5]
Adherence to quality indicators and surveillance guidelines in the management of Barrett's esophagus: a retrospective analysis.

Endosc Int Open. 2018-3

[6]
Barrett's oesophagus: Current controversies.

World J Gastroenterol. 2017-7-28

本文引用的文献

[1]
Barrett's oesophagus: Evidence from the current meta-analyses.

World J Gastrointest Pathophysiol. 2014-8-15

[2]
Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

World J Gastroenterol. 2014-7-28

[3]
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.

JAMA. 2014-3-26

[4]
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Gut. 2013-10-28

[5]
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.

Clin Gastroenterol Hepatol. 2013-3-1

[6]
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

Clin Gastroenterol Hepatol. 2013-1-26

[7]
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus.

PLoS One. 2013-1-3

[8]
Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population.

Int J Cancer. 2013-2-12

[9]
Risk factors in the development of esophageal adenocarcinoma.

Am J Gastroenterol. 2012-12-18

[10]
The impact of the vitamins A, C and E in the prevention of gastroesophageal reflux disease, Barrett's oesophagus and oesophageal adenocarcinoma.

Coll Antropol. 2012-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索